Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Intercept Pharmaceuticals Inc

Regulatory Update On Intercept Pharma's Obeticholic Acid For NASH Delayed Again

Intercept Pharmaceuticals Inc's (NASDAQ:ICPT) pre-submission meeting to discuss the marketing application for obeticholic acid (OCA) in NASH has been moved to July (vs. June scheduling). The update follows a recent request from the FDA that topline data from the REGENERATE reanalysis be provided to the agency for review before the meeting. SVB Leerink…

Benzinga · Jun 6, 2022

Analysts Expect Clarity Imminent On Intercept's NASH Story

Analysts Expect Clarity Imminent On Intercept's NASH Story

RBC Capital Markets writes that following the Advanz deal, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) should be well-capitalized into make-or-break upcoming readouts for obeticholic acid (OCA) in NASH, with REGENERATE re-analyses on deck, REVERSE reading in the next quarter. The analysts say it remains challenging to get visibility on how the efficacy/safety analyses will look,…

Benzinga · May 9, 2022

Why Intercept Shares Are Rising Today

Why Intercept Shares Are Rising Today

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has

Benzinga · May 5, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1

Coverage From

Benzinga

Organisations

RBC Capital Markets

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

423,723 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play